Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first‐line therapy for triple‐negative, metastatic, or locally advanced breast cancer: Results from the GINECO A‐TaXel phase 2 study

Ferrero, Jean-­Marc; Hardy‐Bessard, Anne‐Claire; Capitain, Olivier; Lortholary, Alain; Salles, Bruno César Corrêa; Follana, Philippe; Hervé, Robert; Deblock, Mathilde; Dauba, Jérôme; Atlassi, Mustapha; Largillier, R.

doi:10.1002/cncr.30170

Cited by 24 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on a relatively large sample size, we could explore the curative effect of capecitabine as maintenance therapy for de novo metastatic NPC. Used as a maintenance therapy regimen, capecitabine also showed treatment effects on other metastatic malignancies [20,30,31]. According to a randomized, open-labeled, multicenter phase III trial, the application of capecitabine maintenance therapy significantly prolonged the survival of metastatic colorectal cancer patients and was considered to have acceptable toxicities [20].…”

Section: Discussionmentioning

confidence: 99%

The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study

Sun

Liu

Lan

et al. 2020

Cancer Communications

View full text Add to dashboard Cite

Background Capecitabine was previously used as a second‐line or salvage therapy for metastatic nasopharyngeal carcinoma (NPC) and has shown satisfactory curative effect as maintenance therapy in other metastatic cancers. This study aimed to explore the role of capecitabine as maintenance therapy in de novo metastatic NPC patients with different plasma Epstein‐Barr virus (EBV) DNA levels before treatment. Methods We selected de novo metastatic NPC patients treated with locoregional radiotherapy (LRRT) for this retrospective study. The propensity score matching (PSM) was applied to balance potential confounders between patients who underwent capecitabine maintenance therapy and those who did not with a ratio of 1:3. Overall survival (OS) was the primary endpoint. The association between capecitabine maintenance therapy and survival was assessed using the log‐rank test and a Cox proportional hazard model. Results Among all patients eligible for this study, 64 received capecitabine maintenance therapy after LRRT. After PSM, 192 patients were identified in the non‐maintenance group. In the matched cohort, patients treated with capecitabine achieved a higher 3‐year OS rate compared with patients in the non‐maintenance group (68.5% vs. 61.8%, P = 0.037). Multivariate analysis demonstrated that capecitabine maintenance therapy was an independent prognostic factor. In subgroup analysis, 3‐year OS rate was comparable between the maintenance and non‐maintenance groups in patients with high pretreatment EBV DNA levels (˃30,000 copies/mL) (54.8% vs. 45.8%, P = 0.835), whereas patients with low pretreatment EBV DNA levels (≤30,000 copies/mL) could benefit from capecitabine maintenance therapy in OS (90.0% vs. 68.1%, P = 0.003). Conclusion Capecitabine maintenance therapy may be superior to non‐maintenance therapy in prolonging OS for de novo metastatic NPC patients with pretreatment EBV DNA ≤ 30,000 copies/mL.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study

Sun

Liu

Lan

et al. 2020

Cancer Communications

View full text Add to dashboard Cite

show abstract

“…[20][21][22][23][24][25][26] Urothelial cancer is the most agressive disease and have a low response rate especially after the firstline therapy in its advanced stage. The treatment break for patients who responded to first-line therapy is generally shortterm for about 2 to 3 months and it leads to rapid clinical progression and deterioration.…”

Section: Discussionmentioning

confidence: 99%

Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival

Kuş

Aktaş

2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: To investigate the effects of gemcitabine maintenance treatment on survival in patients with metastatic bladder cancer. Material and methods:Gemcitabine maintenance monotherapy was administered following the standard platinum-gemcitabine therapy in patients with metastatic bladder cancer. Patients who had responded to standard treatment received maintenance gemcitabine therapy as 1000 mg/m 2 on days 1 and 8 every three weeks until progression or development of unacceptable toxicity. The following clinical factors were noted: performance status, age, sex, stage, site of metastasis, choice of cisplatin-gemcitabine or carboplatin-gemcitabine, response rates to the initial chemotherapy. Progression-free survival (PFS) and overall survival (OS) for standard treatment, and following gemcitabine monotreatment and for maintenance gemcitabine therapy were calculated using Kaplan-Meier method.Results: A total of 88 patients with metastatic bladder cancer treated between February 2009 to October 2015 were evaluated retrospectively and 23 patients (26.1%) who had responded to six cycles of platinumgemcitabine treatment were included in this study. Maintenance gamcitabine was administered for a median of 7 times (range 3-14 times). Grade 3 hematotoxicity according to the criteria of the Common Terminology Criteria of Adverse Events was observed in 7 (30.4%) patients. Median PFS of patients was 46 (range: 30-82) weeks for platinum-based treatment plus maintenance gemcitabine therapy. A higher median PFS was obtained in patients who were <65 year-olds, without organ metastasis with objective response rate, however, it was statistically insignificant. Conclusion:Gemcitabine maintenance therapy in metastatic bladder cancer patients who did not shown progression after the standard platinum-gemcitabine treatment contributes to survival and presents low toxicity profile, when compared to historical controls.

show abstract

“…Application of apatinib after multifaceted therapies for metastatic breast cancer receptor family contribute substantially to tumor growth (3). The VEGF-A monoclonal antibody bevacizumab, combined with chemotherapy, was found to significantly increase the objective response rate (ORR) and progressionfree survival (PFS) of patients with metastatic triplenegative breast cancer as a first choice therapy (4)(5)(6). Used as second-line treatment, this combination not only improved PFS, but also tended to enhance overall survival (OS) of patients (7).…”

Section: Original Articlementioning

confidence: 99%

Application of apatinib after multifaceted therapies for metastatic breast cancer

Wang¹,

Chen²,

Chen³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Apatinib is a small molecule tyrosine kinase inhibitor (TKI) that is taken orally and has high specificity for vascular endothelial growth factor receptor 2 (VEGFR-2). This study explored the efficacy and toxicity of apatinib in patients with metastatic breast cancer (MBC) who failed to respond to multifaceted therapy. Methods: A total of 61 patients with MBC who were unresponsive to previous multifaceted chemotherapy were included in this study. The treatment regimens were either a combination of apatinib and chemotherapy or apatinib administered singly with a dose range of 250 mg every second day to 500 mg per day. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and toxicity were used as outcome measures. Results: Of the 61 patients, partial response (PR) was observed in 14 patients (23.0%), stable disease (SD) was observed in 30 patients (49.2%), and progressive disease (PD) was observed in 17 patients (27.8%). The DCR was 44/61 (72.1%), and the ORR was 14/61 (23.0%). Of the 44 patients who achieved PR or SD, the median PFS was 4 months and 15 days. Patients with intracranial metastases were found to benefit from apatinib. Furthermore, 11 patients underwent next generation sequencing (NGS) and 5 of these had a P53 mutation. Of those 5 cases, the ORR and DCR were 0% and 20.0%, respectively. Of the 6 cases with wild-type P53, the ORR was 50.0%, and the DCR was 100.0%. Multivariate regression analysis found that hypertension was an independent prognostic factor of better DCR. Conclusions: Apatinib showed good efficacy and manageable toxicity in patients with MBC that had not responded to multifaceted therapy.

show abstract

Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first‐line therapy for triple‐negative, metastatic, or locally advanced breast cancer: Results from the GINECO A‐TaXel phase 2 study

Cited by 24 publications

References 28 publications

The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study

The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study

Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival

Application of apatinib after multifaceted therapies for metastatic breast cancer

Contact Info

Product

Resources

About